|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Stenting for symptomatic intracranial arterial stenosis in China:1-year outcome of a multicentre registry study显示文摘background and purpose A multicentre prospective registry study of individually tailored stenting for a patient with symptomatic intracranial atherosclerotic stenosis(ICAS)combined with poor collaterals in China showed that the short-term safety and efficacy of stenting was acceptable.However,it remained uncertain whether the low event rate could be of a long term.We reported the 1-year outcome of this registry study to evaluate the long-term efficacy of individually tailored stenting for patients with severe symptomatic ICAS combined with poor collaterals.Methods Patients with symptomatic ICAS caused by 70%-99% stenosis located at the intracranial internal carotid,middle cerebral,intracranial vertebral or basilar arteries combined with poor collaterals were enrolled.Balloon-mounted stent or balloon plus self-expanding stent were selected based on the ease of vascular access and lesion morphology determined by the operators.The primary outcome was the rate of 30-day stroke,transient ischaemic attack and death,and 12-month ischaemic stroke within the same vascular territory,haemorrhagic stroke and vascular death after stenting.results From September 2013 to January 2015,300 patients(ages 58.3±9.78 years)were recruited.Among them,159 patients were treated with balloon-mounted stent and 141 with balloon plus self-expanding stent.During the 1-year follow-up,25 patients had a primary end point event.The probability of primary outcome at 1 year was 8.1%(95% CI 5.3% to 11.7%).In 76 patients with digital subtraction angiography follow-up,27.6%(21/76)had re-stenosis≥50% and 18.4%(14/76)had re-stenosis≥70%.No baseline characteristic was associated with the primary outcome.Conclusion The event rate remains low over 1 year of individually tailored stenting for patients with severe symptomatic ICAS combined with poor collaterals.Further randomised trial of comparing individually tailored stenting with best medical therapy is needed. | Ning Ma Yong Zhang Jie Shuai Changchun Jiang Qiyi Zhu Kangning Chen Li Liu Baomin Li Xiangqun Shi Lianbo Gao Yajie Liu Feng Wang Yongli Li Tieyan Liu Hongbo Zheng Dapeng Mo Feng Gao Yilong Wang Yongjun Wang Lei Feng Zhongrong Miao | 2018 | Stroke & Vascular Neurology2018，3，3： | 29 |
| 2 | Staged carotid artery angioplasty and stenting for patients with high-grade carotid stenosis with high risk of developing hyperperfusion injury:a retrospective analysis of 44 cases显示文摘Background:Hyperperfusion syndrome(HPS)is a rare but potentially a life-threatening complication after carotid artery angioplasty and stenting(CAS).Staged CAS has been an alternative to prevent HPS.Materials and methods:44 of 908 patients with high-grade internal carotid artery stenosis or near occlusion were at risk of HPS because of poor collateral flow and impaired cerebral blood flow(CBF).They were treated with first(stage 1),followed by a full CAS(stage 2)1 month later.Their 30-day outcomes were tabulated and analysed.Results:During follow-up,1 of the 44(2.2%)patients developed HPS immediately,3(7%)had postprocedural HPS(ie,transcranial Doppler(TCD)>120%)without clinical symptoms and 3(7%)required stenting at stage 1 for carotid dissections.After stage 1,there were significant improvement between the preprocedural and postprocedural CBF(0.98±0.06 vs 0.85±0.05,p<0.05),mean transit time(MTT;1.05±0.05 vs 1.15±0.05,p<0.05),time to peak(TTP;1.04±0.06 vs 1.20±0.06,p<0.05)on CT perfusion(CTP),and CBF(66.41±7.41 vs 44.44±6.43,p<0.05)on TCD.After stage 2,improvement was seen in CBF(1.01±0.07 vs 0.98±0.06,p<0.05),MTT(1.01±0.05 vs 1.05±0.05,p<0.05),TTP(0.99±0.06 vs 1.04±0.06,p<0.05)on CTP and CBF(66.41±7.41 vs 93.78±18.81,p<0.05)on TCD.2 had postoperative increase of middle cerebral artery mean flow velocity of 120%after stage 2 without clinical symptoms.Conclusion:Staged carotid artery stenting probably decreased the chance of developing HPS in this group of selected patients.Although requiring a 2-step intervention,staged CAS may be a safe and effective alternative. | Dapeng Mo Gang Luo Bo Wang Ning Ma Feng Gao Xuan Sun Xiaotong Xu Zhongrong Miao | 2016 | Stroke & Vascular Neurology2016，1，4： | 14 |
| 3 | Endovascular revascularisation of acute tandem vertebrobasilar artery occlusion:seven case series with literature reviews显示文摘background The outcome of acute ischaemic stroke due to tandem vertebrobasilar artery occlusion was poor.Endovascular revascularisation may be a positive approach for acute basilar artery occlusion combined with vertebral ostium stenosis or occlusion.We reported seven patients with acute vertebrobasilar tandem occlusion by using angioplasty or stenting for proximal lesion and thrombectomy for distal occlusion.Materials and methods Consecutive patients with acute tandem vertebrobasilar artery occlusion at two centres were included in this study.We retrospectively analysed the clinical,technical and functional outcomes of the patients.results From March 2016 to March 2017,seven patients were included.The mean age and National Institute of Health Stroke Scale score at admission was 57 years and 22,respectively.A reverse approach was used in five patients.The Thrombolysis in Cerebral Infarction score 2b-3 was acquired in all patients.There were no procedural complications.The modified Rankin Scale score was 1-2 for three patients and 4 for one patient at 3 months.Three patients died at 3 months of follow-up.Conclusions Endovascular revascularisation may be feasible for acute tandem vertebrobasilar artery occlusion,and more researches are needed. | Haihua Yang Ning Ma Shiyong Zhang Xiaochuan Huo Feng Gao Xuan Sun Dapeng Mo Zhongrong Miao | 2018 | Stroke & Vascular Neurology2018，3，1： | 10 |
| 4 | 3-year Treatment of Tenofovir Alafenamide vs.Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China显示文摘Background and Aims:Tenofovir alafenamide(TAF)has similar efficacy to tenofovir disoproxil fumarate(TDF)but with improved renal and bone safety in chronic hepatitis B patients studied outside of China.We report 3-year results from two phase 3 studies with TAF in China(Clinicaltrials.gov:NCT02836249 and NCT02836236).Methods:Chinese hepatitis B e antigen(HBeAg)-positive and-negative chronic hepatitis B patients with viremia and elevated alanine aminotransferase were randomized 2:1 to TAF or TDF treatment groups and treated in a double-blind fashion for 144 weeks(3 years).Efficacy responses were assessed by individual study while safety was assessed by a pooled analysis.Results:Of the 334 patients(180 HBeAg-positive and 154 HBeAg-negative)randomized and treated,baseline characteristics were similar between groups.The overall mean age was 38 years and 73%were male.The mean HBV DNA was 6.4 log10 IU/mL.The median alanine aminotransferase was 88 U/L,and 37%had a history of antiviral use.At week 144,the proportion with HBV DNA<29 IU/mL was similar among the two groups,with TAF at 83%vs.TDF at 79%,and TAF at 93%vs.TDF at 92%for the HBeAg-positive and-negative patients,respectively.In each study,higher proportions of TAF than TDF patients showed normalized alanine aminotransferase(via the American Association for the Study of Liver Diseases and the China criteria)and showed loss of HBsAg;meanwhile,the HBeAg seroconversion rates were similar.Treatment was well-tolerated among the TAF patients,who showed a smaller median decline in creatinine clearance(−0.4 vs.−3.2 mL/min;p=0.014)and less percentage change in bone mineral density vs.TDF at hip(−0.95%vs.−1.93%)and spine(+0.35%vs.−1.40%).Conclusions:In chronic hepatitis B patients from China,TAF treatment provided efficacy similar to TDF but with better renal and bone safety at 3 years. | Jinlin Hou Qin Ning Zhongping Duan You Chen Qing Xie Fu-Sheng Wang Lunli Zhang Shanming Wu Hong Tang Jun Li Feng Lin Yongfeng Yang Guozhong Gong John FFlaherty Anuj Gaggar Shuyuan Mo Cong Cheng Gregory Camus Chengwei Chen Yan Huang Jidong Jia Mingxiang Zhang GS-US-320-0110 and GS-US-320-0108 China Investigators | 2021 | Journal of Clinical and Translational Hepatology2021，9，3： | 7 |
| 5 | 表面深滚处理对AZ91镁合金组织及性能的影响(英文)显示文摘在室温下对固溶处理后的AZ91 镁合金块体材料进行表面深滚处理,以研究其对合金表面显微组织和力学性能的影响。分析被加工试样表层沿深度方向的显微硬度和显微组织。结果表明,表面影响层厚度达到2.0 mm,可分为3 个亚层:从最表面起约为400μm 厚的严重变形层,大约600μm 厚的中等变形层和厚度达1000μm 的小变形层。在变形层中除晶粒细化外,还观察到应变诱导析出的β相(Mg17Al12),尤其是在严重变形层和中等变形层内。研究认为,晶粒细化、应变硬化和沉淀强化的协同作用使AZ91 镁合金在表面深滚后的硬度显著提高。 | 罗贤 Qi-yang TAN Ning MO Yu YIN 杨延清 Wyman ZHUANG Ming-xing ZHANG | 2019 | Transactions of Nonferrous Metals Society of China2019，29，7： | 7 |
| 6 | Low- and high-dose hydrogen peroxide regulation of transcription factor NF-E2-related factor 2显示文摘背景反应的氧种类(ROS ) 可以玩生理并且 pathophysiological 角色。(Nrf2 ) 抄写因素 NF-E2-related 因素 2 调整抗氧化剂反应元素() 响应物理、化学的压力的 chemoprotective 蛋白质的调停的基因表示和坐标正式就职。在对氧化压力遗体 unknown.Methods 老鼠肺的 microvascular endothelial 房间的不同层次的细胞的回答的 Nrf2 的准确角色与 0 mmol/L, 0.125 mmol/L, 0.25 mmol/L, 0.5 mmol/L, 1.0 mmol/L 和 2.0 mmol/L 有教养、对待 2 个小时的氢过氧化物答案。 Nrf2 基因表示是由反向的 transcription-PCR 的 assayed , Nrf2 有约束力的活动是有 electrophoretic 活动性移动试金( EMSA )的 assayed ,并且 Nrf2 的本地化与低、中等的 immunohistochemistry.Results 被检测( 0.125 mmol/L , 0.25 mmol/L 和 0.5 mmol/L )老鼠的剂量氢过氧化物暴露肺的 microvascular endothelial 房间导致了 Nrf2 的原子累积,抄写规定的增加的活动和药物治疗的起来规定基因表示。相反,高氢过氧化物开( 1 mmol/L , 2 mmol/L )房间的暴露导致了 Nrf2 ,减少的活动抄写规定和氢过氧化物的低、中等的剂量玩的调停基因 expression.Conclusion 的下面规定的原子排除由增加 Nrf2 的抄写活动的保护的角色,而高--剂量氢过氧化物由 Nrf2 的减少的抄写活动起一个有害作用。 | NING Jiao-lin MO Li-wen LAI Xi-nan | 2010 | Chinese Medical Journal2010，，8： | 7 |
| 7 | Advances in postoperative adjuvant therapy for primary liver cancer显示文摘Hepatocellular carcinoma(HCC)is a highly heterogeneous,invasive,and conventional chemotherapy-insensitive tumor with unique biological characteristics.The main methods for the radical treatment of HCC are surgical resection or liver transplantation.However,recurrence rates are as high as 50%and 70%at 3 and 5 years after liver resection,respectively,and even in Milan-eligible recipients,the recurrence rate is approximately 20%at 5 years after liver transplantation.Therefore,reducing the postoperative recurrence rate is key to improving the overall outcome of liver cancer.This review discusses the risk factors for recurrence in patients with HCC radical surgical resection and adjuvant treatment options that may reduce the risk of recurrence and improve overall survival,including local adjuvant therapy(e.g.,transcatheter arterial chemoembolization),adjuvant systemic therapy(e.g.,molecular targeted agents and immunotherapy),and other adjuvant therapies(e.g.,antiviral and herbal therapy).Finally,potential research directions that may change the paradigm of adjuvant therapy for HCC are analyzed. | Zhi-Ming Zeng Ning Mo Jie Zeng Fu-Chao Ma Yan-Feng Jiang Hua-Sheng Huang Xi-Wen Liao Guang-Zhi Zhu Jie Ma Tao Peng | 2022 | World Journal of Gastrointestinal Oncology2022，14，9： | 5 |
| 8 | Reversibly enhanced aqueous solubilization of volatile organic compounds using a redox-reversible surfactant显示文摘Surfactant-enhanced remediation (SER) is an effective method for the removal of volatile organic compounds (VOCs) from contaminated soils and groundwater.To reuse the surfactant the VOCs must be separated from the surfactant solutions.The water solubility of VOCs can be enhanced using reversible surfactants with a redox-acive group,(ferrocenylmethyl)dodecyldimethylammonium bromide (Fc12) and (ferrocenylmethyl)tetradecanedimethylammonium bromide (Fc14),above and below their critical micelle concentrations (CMC) under reducing (I + ) and oxidative (I 2+ ) conditions.The CMC values of Fc12 and Fc14 in I + are 0.94 and 0.56 mmol/L and the solubilization of toluene by Fc12 and Fc14 in I + for toluene is higher than the solubilization achieved with sodium dodecyl sulfate,cetyltrimethylammonium bromide and Trition X-114.The solubilization capacity of the ferrocenyl surfactants for each tested VOCs ranked as follows: ethylbenzene > toluene > benzene.The solubilities of VOCs by reversible surfactant in I + were 30% higher than those in I 2+ at comparable surfactant concentrations.The effects of Fc14 concentrations on VOCs removal efficiency were as follows: benzene > toluene > ethylbenzene.However,an improved removal efficiency was achieved at low ferrocenyl surfactant concentrations.Furthermore,the reversible surfactant could be recycled through chemical approaches to remove organic pollutants,which could significantly reduce the operating costs of SER technology. | Yingjie Li Senlin Tian Hong Mo Ping Ning | 2011 | Journal of Environmental Sciences2011，23，9： | 5 |
| 9 | A comparison between acute large vessel occlusion in the posterior circulation and anterior circulation after endovascular treatment:the ANGEL-ACT registry experience显示文摘Background and purpose Endovascular treatment(EVT)has shown an overwhelming benefit for acute anterior circulation artery occlusion(ACO).Whether it can achieve the same outcomes in posterior circulation artery occlusion(PCO)has not been well explained.We aimed to evaluate the characteristics and prognosis of ACO and PCO after EVT in a nationwide registry.Method The present analysis was based on the prospective ANGEL-ACT Registry in China between November 2017 and March 2019.Demographic data,periprocedural times,recanalisation rate,intracranial haemorrhage(ICH)and 90-day functional outcomes were compared between the ACO and PCO groups.Results A total of 1793 patients were analysed including 397(22.1%)consecutive patients with PCO and 1396(77.9%)patients with ACO treated with EVT.A larger proportion of patients with PCO had intracranial atherosclerotic disease and received extra angioplasty during EVT.Successful recanalisation and 90-day favourable functional outcomes did not differ significantly between the two groups.Patients with PCO showed lower 24-hour ICH and symptomatic ICH rates.There was a trend towards higher mortality rate in the PCO group(22.09%vs 14.44%;adjusted OR 1.286(95%CI 0.820 to 2.017),p=0.2731),especially when the onset to puncture time was over 6 hours(30.77%vs 11.13%;adjusted OR 2.673(95%CI 1.280 to 5.583),p=0.0089,interactive p=0.0002).Conclusions In this large prospective multicentre registry,there was a significant difference in the characteristics and periprocedural features between patients with PCO and ACO.However,successful recanalisation and 90-day favourable functional outcomes in PCO were equivalent to those in ACO. | Xuan Sun Jingyu Zhang Xu Tong Baixue Jia Dapeng Mo Ning Ma Feng Gao Lian Liu Xiaochuan Huo Ligang Song Yiming Deng Zhongrong Miao | 2022 | Stroke & Vascular Neurology2022，7，4： | 4 |
| 10 | Staged angioplasty versus regular carotid artery stenting in patients with carotid artery stenosis at high risk of hyperperfusion:a randomised clinical trial显示文摘Background and purpose Hyperperfusion(HP)is a devastating complication associated with carotid artery stenting(CAS)or endarterectomy.The efficacy and safety of staged angioplasty(SAP)in patients with CAS at high risk of HP remains unclear.We sought to determine whether SAP is superior to regular CAS in patients with high risk of HP.Methods A randomised,multicentre open-label clinical trial with blinded outcome assessment(STEP)was conducted.Patients with severe carotid stenosis at high risk of HP were randomly assigned(1:1)to the SAP or regular CAS group.The primary endpoint was hyperperfusion syndrome(HPS)and intracerebral haemorrhage(ICH)within 30 days after the procedure.Results From November 2014 to January 2017,a total of 64 patients were enrolled in 11 centres.33 patients were allocated to the SAP group and 31 to the regular CAS group.At 30 days,the rate of primary endpoint was 0.0%(0/33)in the SAP group and 9.7%(3/31)in the regular CAS group(absolute risk reduction(ARR),9.7%;95%CI−20.1% to 0.7%;p=0.11).As one of the secondary endpoints,the incidence of HP phenomenon(HPP)was lower in the SAP group than the regular CAS group(0.0%vs 22.6%,ARR,−22.6%;95% CI−36.8%to−10.2%;p=0.04).Conclusion The rate of HPS and ICH was not significantly lower in SAP group;the extended secondary endpoint of HPP,however,significantly reduced,which suggested that SAP may be a safe and effective carotid revascularisation procedure to prevent HP. | Dapeng Mo Baixue Jia Huaizhang Shi Yaxuan Sun Qingan Liu Chengzhe Fan Jianping Deng Jinglin Yuan Wei Wu Changchun Jiang Guilian Zhang Hanjun Du Ning Ma Feng Gao Xuan Sun Ligang Song Lian Liu Guangge Peng Yongjun Wang Yilong Wang Zhongrong Miao the STEP Study Group | 2021 | Stroke & Vascular Neurology2021，6，1： | 3 |
| 11 | Prognostic value of plasma C-reactive protein in the evaluation of paraquat poisoning patients显示文摘Objective: To investigate the prognostic value of plasma C-reactive protein(CRP) level in patients with paraquat poisoning.Methods: This study included 162 patients with paraquat poisoning. The data of plasma paraquat, CRP level and arterial blood gas were analyzed. Cox regression analysis was applied to evaluate the risk factors of prognosis. Receiver operating characteristics curve analysis and area under curve were used to calculate the predictive power of significant variable. Differences in patient survival were determined using the Kaplan–Meier method and a log-rank test.Results: Plasma CRP level was significantly increased in non-survival patients compared with survival patients(P < 0.05), and positively correlated with plasma paraquat level(P < 0.05). Cox regression analysis revealed that plasma CRP level was an independent prognostic marker of mortality within 30 days. The receiver operating characteristics curve analysis indicated that area under curve of plasma CRP level was0.867(95% CI: 0.81–0.93), and the cut-off value was 18 mg/L, and patients with CRP level over this value had a poor survival time compared with those with less than this value.Conclusions: These results suggest that plasma CRP level is distinct increased in patients with paraquat poisoning, and the plasma CRP level may be useful for the prediction of prognosis in paraquat poisoning. | Zong Ning Yu-Long Bai Hua Lu Kang-Lin Mo | 2015 | Asian Pacific Journal of Tropical Biomedicine2015，5，10： | 3 |
| 12 | Acute Ischaemic Stroke Cooperation Group of Endovascular Treatment (ANGEL) registry: study protocol for a prospective, multicentre registry in China显示文摘Background and purpose Endovascular treatment could improve functional outcomes and reduce mortality in patients with intracranial large artery occlusion. This registry aims to evaluate the endovascular treatment delivery and to improve endovascular treatment algorithm in clinical practice for patients with stroke in China. Methods and analysis This multicentric, nationwide, prospective registry plans to include 20 stroke centres and recruit 900 consecutive AIS patients with large- artery occlusion under endovascular treatment. This registry will enrol acute large vessel occlusion patients suitable for endovascular treatment and the inclusion and exclusion criteria. In this study, 90 days functional independence (modified Rankin Scale score ≤2) is the primary efficacy endpoint. The procedural efficacy endpoint of this registry is target artery recanalisation defined by modified Thrombolysis in Cerebral Infarction score 2b or 3 after endovascular therapy. Symptomatic intracranial haemorrhage with 24±3 hours after the procedure is the primary safety endpoint of this registry. Ethics and dissemination Beijing Tiantan Hospital’s Ethics committee and all other participating centres approved the protocol and data collection of Acute Ischaemic Stroke Cooperation Group of Endovascular Treatment registry. Each participant or representative had a written informed consent. | Xiaochuan Huo Ning Ma Dapeng Mo Feng Gao Ming Yang Yilong Wang Yongjun Wang Zhongrong Miao ANGEL investigators | 2019 | Stroke & Vascular Neurology2019，4，1： | 2 |
| 13 | Genetic Characterization of Two Human Cases Infected with the Avian Influenza A(H5N6)Viruses—Guangxi Zhuang Autonomous Region,China,2021显示文摘Summary What is known about this topic?H5N6 has replaced H5N1 as a dominant avian influenza virus(AIV)subtype in southern China.The increasing genetic diversity and geographical distribution of H5N6 pose a serious threat to the poultry industry and human health.What is added by this report?A total of 2 cases of H5N6 that occurred from February 2021 to July 2021 in Guangxi. | Fuyin Bi Lili Jiang Lihua Huang Jingguang Wei Xiaowen Pan Yu Ju Jianjun Mo Minmei Chen Ning Kang Yi Tan Yonghong Li Jing Wang | 2021 | China CDC weekly2021，3，44： | 2 |
| 14 | Angioplasty with Stent for Symptomatic Intracranial Stenosis Trial I (ASSIT-Ⅰ) Study显示文摘Background and Purpose Annual stroke rates might be as high as 10% to 24% in patients with symptomatic intracranial stenosis on best medical therapy. Angioplasty with stent for symptomatic intracranial stenosis trial Ⅰ (ASSIST-Ⅰ) was a prospective and nonrandomized feasibility and safety study to evaluate the APOLLO Stent System for treatment of symptomatic intracranial artery stenosis, and prepare for ASSIST Ⅱ-a prospective, multicenter,and randomized controlled-study. The APOLLO stent delivery system (MicroPort Medical [Shanghai] Limited Co.), specifically designed for intracranial artery stenosis, consists of a stent and a balloon and a rapid-exchange delivery catheter. The stent is made of 316L stainless steel, with diameters of 2.0 to 4.0 mm and length of 8 mm or 13 mm. Only two links connect the rings of 1 mm in length, rendering the stent a good flexibility enough to navigate tortuous intracranial vessels. The nominated pressure of the stent is designed at 6 atm to reduce the risk of occlusion to side branches and perforators and rupture and dissection of target vessel. The crimping technique is applied in this system, insuring a compact ability of stent so wonderful that the struts of stent do not lift when the stent negotiates a turn, which lessen the likelihood of vessel wall injury and stent migrating. Materials and methods Thirty-four patients with 35 symptomatic intracranial stenoses of ≥50%, which resulted in transient ischemic attacks (TIAs [23 lesions /22 patients]) and minor stroke (7 lesions/7 patents), and both TIAs and stroke (5 lesions/ 5 patients), and with 1 asymptomatic severe stenosis, were enrolled in ASSIST-Ⅰ from December 10, 2003 to August 12, 2004. Their age was 54.3 years±SD of 9.49, three patients were male, and all had ≥1 risk factors of atherosclerosis. Patients received the evaluation of National Institutes of Health Stroke Scale (NIHSS), modified Rankin scale (mRS )and Barthel idex (BI) before and one-, three-, six-, and 12-month after the procedure. Results Stent success, defined as stent-assisted angioplasty successfully, resulting in ≤20% residual stenosis, was obtained in 35 lesions ( 97.2%, 35/36) and 33 patients ( 97.1%, 33/34). The stenosis rate of pre- and post -procedure was 80.5%± SD of 12.65 and 7.4%±SD 15.74, respectively. The Procedure-related complications were 8.3% for lesion (3/36) and 8.8% for patient (3/34), included 1 acute thrombosis, which obtained complete patency by means of intrathrombus thombolysis at once without sequelae, and 2 ischemic perforator strokes (1 irreversible stroke and 1 reversible). The disable stroke, defined as one that led to mRS score of ≥2, 30 days after the stroke, occurred in one patient ( 2.9%, 1/34; mRS of 2). Procedure success, defined as stent success without disable stroke or death at discharge by means of the endovascular therapy, was achieved in 33 lesions ( 91.7%, 33/36) and in 31 patients ( 91.2%, 31/34). Treatment success, defined as stent success without disable stroke and death at the 30th day, by means of the endovascular and medical therapy, was obtained in 34 lesions ( 94.4%, 34/36) and 32 patients ( 94.1%, 32/34). Clinical Follow-up, median 170 days (ranged from 30 days to 273 days; ≥1 month, n=34; ≥3 months, n=23; ≥6 months, n=13), was performed in 34 patients. There were no ischemic neurological events and death occurred. Cumulated disable stroke occurred in 1 patient ( 2.9%, 1/34). NIHSS was 1.09±SD of 1.694 and 0.47±SD of 1.051, before procedure and at the 30th day (n=34), respectively, and 0.57±SD of 0.992 at 3 months (n=23), 0.15±SD of 0.376 at 6 months (n=13), respectively; mRS was 0.65±SD of 0.812 and 0.47±SD of 0.563, before procedure and at 30 days, respectively, and 0.61±SD of 0.583 at 3 months, 0.38±SD of 0.506 at 6 months, respectively; and BI was 97.54±SD of 5.918 and 99.26±SD of 2.179, before procedure and at 30 days, respectively, and 99.35±SD of 2.288 at 3 months, 100.00±SD | Wei-Jian Jiang, MD Min Jin, MD Bin Du, MD Yong-Jun Wang, MD Xiao-Tong Xu, MD Qing-He Wang, MD Ning Ma, MD Long-Yi Wang, MO Jian-Ping Dai, MD From the Neurovascular Angioplasty Team, Department of Neurology and Neuroradiology, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing, China. Correspondence to Wei-Jian Jiang, MD, Department of Neurology and Neuroradiology, Beijing Tiantan Hospital, Capital University of Medical Sciences, Beijing, 100050, China. | 2004 | 介入放射学杂志2004，13，S1： | 2 |
| 15 | Inhibition of autophagy enhances the radiosensitivity of nasopharyngealcarcinoma by reducing Rad51 expression显示文摘 | Ning Mo Yong-Kui Lu Wei-Min Xie Yan Liu Wen-Xian Zhou Hong-Xue Wang Li Nong Yu-Xian Jia Ai-Hua Tan Ying Chen Shan-Shan Li Bao-Hua Luo | 2014 | Oncology Reports2014，，5： | 1 |
| 16 | Sodium Hydrosulphide alleviates remote lung injury following limb traumatic injury in rats 显示文摘 | Ning J Mo L Zhao H | 2013 | PLoS 0ne2013，8，3： | 1 |
| 17 | Effect of Different Factors on the Quality of Life and Sequelae of COVID-19 Patients After Discharge显示文摘Background The continued spread of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)remains an international public health emergency,resulting in a significant global disease burden.The long-term effects of SARS-CoV-2 infection in humans and the long-term prognosis of patients with coronavirus disease 2019(COVID-19)after discharge remain unclear.We aimed to assess the quality of life(QoL)and sequelae in patients with COVID-19 after discharge from the hospital by conducting multiple follow-up visits to understand the long-term effects of SARS-CoV-2 on patients'health and its possible influencing factors.Methods COVID-19 patients discharged from Huoshenshan Hospital(Wuhan,China)between February 15 and April 5,2020,were followed up at 6,9,and 12 months after discharge.They completed questionnaires on postdischarge QoL and sequelae under the guidance of medical staff with professional training.The demographic and clinical characteristics of the COVID-19 patients were analyzed using descriptive statistics.A generalized estimating equation model was used to analyze the QoL-related factors.Theχ2 test(or Fisher exact test)and multivariate logistic regression analysis were used to analyze the sequelae and influencing factors.Results A total of 175 patients participated in at least 1 follow-up visit,and 120 completed all 3 follow-up visits.Patients diagnosed with severe and critically ill COVID-19 had worse mental conditions(χ2=7.653,P=0.022)than those with the nonsevere type(not severe or critical)and were more likely to feel fatigued(χ2=4.836,P=0.028).Female patients had a higher risk of sleep disturbance(χ2=10.026,P=0.002)and dyspnea(χ2=5.672,P=0.017)and had more difficulty returning to their original work and life(χ2=8.922,P=0.003)than male patients.Patients with diabetes had a worse appetite(χ2=4.669,P=0.031)and were more prone to sleep disturbance(χ2=4.417,P=0.036)after discharge.The proportion of patients with at least 1 sequela increased from 29.76%(50/168)at 6 months to 51.11%(69/135)at 9 months(χ2=14.305,P<0.001).Compared with the nonsevere type,patients diagnosed with severe and critically ill COVID-19 had an odds ratio(OR)of 4.325(95%confidence interval[CI],1.215–15.401)for memory decline.Female patients had an OR of 4.632(95%CI,1.716–12.501)for joint or muscle pain.Patients with hypertension had an OR of 3.014(95%CI,1.193–7.615)for joint or muscle pain.Conclusion One year after discharge,there were still some patients with varying degrees of decline in QoL and sequelae,which occurred in all follow-up visits.Moreover,QoL and sequelae after discharge were related to sex,clinical classification of COVID-19,and underlying diseases. | Nan Guo Ya-Ping Yao Le Song Guan-Zhen Wang Jun-Li He Ning Zheng Qiong Mo Wen-Xu Ni Bo Zhang Fu-Sheng Wang Lei Huang | 2023 | Infectious Diseases & Immunity2023，3，2： | 1 |
| 18 | Sodium Hydrosulphide alleviates re-mote lung injury following limb traumatic injury in rats显示文摘 | Ning J Mo L Zhao H | 2013 | PLoS One2013，8，59： | 1 |
| 19 | Crystal Transformation of Nylon 11 Using in situ WAXD显示文摘α Form Nylon 11 films were found to exist a non-linear transformation at 70℃ during the heating process using in situ WAXD. The a Form disappeared but δ form appeared when the temperature was higher 70℃. | Qing Xin ZHANG~1 Yu Xian AN~1 Ying Ning YU~1 Zhi Shen MO~1 G. R. MITCHELL~2 (1 Polymer Physics Laboratory. Changchun Institute of Applied Chemistry. Chinese Academy of Sciences. Changchun 130022 2 Department of Physics. University of Reading. Whiteknight | 2000 | Chinese Chemical Letters2000，11，4： | 1 |
| 20 | Effect of solution temperature on shape memory effect of CuZnAl alloy 显示文摘 | Huang Shuke Li Ning Mo Huaqiang | 2005 | Journal of Sichuan University : Engineering Science Edition2005，37，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员